Clinical trial
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
NCT00570765 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
- Lead sponsor
- Intercept Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 17, 2008
- Completion date
- September 25, 2017
- Enrollment
- 60 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.